In the News

---

Breye raises €67.5 million for retinal disease therapies

01 October 2026
Drug Discovery World
View Story

---

Breye Therapeutics raises $75.6m for oral NPDR drug

05 October 2026
BioXconomy
View Story

---

Breye Raises €67.5M for Oral DR Therapy

06 October 2026
The Opthalmologist
View Story

---

Ascletis challenges psoriasis field with pill; Invivyd plans Covid filing, Plus news about Breye, Immix and Aptadir

06 October 2026
Endpoints News
View Story [Behind Paywall]

---

Financings: Sagimet adds $115M in offering; Breye’s $76M series A and more

06 October 2026
BioWorld
View Story [Behind Paywall]

---

Fierce Biotech Fundraising Tracker ’26: Breye bags $76.5M

30 September 2026
Fierce Biotech
View Story

---

Danish biotech Breye raises EUR 67.5m for eye pill derived from Zealand Pharma

30 September 2026
MEDWATCH
View Story [Behind Paywall]

---

Breye Secures Cash Boost For Diabetes-Driven Blindness Pill

29 September 2026
Scrip
View Story [Behind Paywall]

---

Breye raises €67.5M as oral drug for diabetic retinopathy heads to mid-stage study

29 September 2026
FirstWord
View Story

---

Breye raises €67.5M for diabetic eye disease trial with Novo Holdings backing

29 September 2026
European Biotechnology
View Story

---

Pill May Prevent Sight Loss in Diabetic Eye Condition

24 September 2026
Mirage News
View Story

---

Oral Drug Shows Promise in Protecting Against Diabetic Eye Disease

23 September 2026
Inside Precision Medicine
View Story

---

A simple pill could prevent sight loss in diabetes-driven eye condition, early findings suggest

23 September 2026
Medical Xpress
View Story

---

A Simple Pill Could Treat Diabetic Eye Damage Before Vision Is Lost

23 September 2026
SciTechDaily
View Story

---

Our CEO Ulrik Mouritzen spoke with Stephen Adams from Optimum Strategic Communications to discuss the successful completion of the Phase 1b study

21 August 2025